Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM27WDP)

Drug Name
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one Drug Info
Synonyms
oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one; Oxindole I
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5908088
TTD Drug ID
DM27WDP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting PDK-1 messenger RNA (PDK-1 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NU-6102 DMMOFKD Discovery agent N.A. Investigative [3]
BX-517 DMBQIEF Discovery agent N.A. Investigative [1]
ISIS 29475 DMEBQUN Discovery agent N.A. Investigative [4]
ISIS 29233 DMGV4O7 Discovery agent N.A. Investigative [4]
ISIS 29471 DMG4RMZ Discovery agent N.A. Investigative [4]
ISIS 29470 DMPCK7Y Discovery agent N.A. Investigative [4]
ISIS 29477 DMKQMXV Discovery agent N.A. Investigative [4]
ISIS 29239 DMHQF1J Discovery agent N.A. Investigative [4]
SU-6689 DMDNA23 Discovery agent N.A. Investigative [1]
ISIS 29257 DMUM2H1 Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Ret (RET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [2]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [5]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [5]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [6]
Selpercatinib DMZR15V Non-small-cell lung cancer 2C25.Y Approved [7]
Pralsetinib DMWU0I2 Non-small-cell lung cancer 2C25.Y Approved [8]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [9]
CEP-32496 DMAO04B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [11]
GSK3179106 DM2KCIP Inflammatory bowel disease DD72 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Capivasertib DM9SKW8 Breast cancer 2C60-2C65 Approved [10]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [10]
GDC-0068 DMWBZJD Breast cancer 2C60-2C65 Phase 3 [10]
CI-1033 DMSI8N3 Lymphoma 2A80-2A86 Phase 2 [6]
CMX-2043 DMPSCVY Cardiac disease BA00-BE2Z Phase 2 [13]
ARQ 092 DM5WK0J Proteus syndrome LD2C Phase 2 [14]
GSK2110183 DMZHB37 leukaemia 2A60-2B33 Phase 2 [15]
RX-0201 DMTBAV3 Pancreatic cancer 2C10 Phase 2 [16]
PTX-200 DM0ZIT2 Breast cancer 2C60-2C65 Phase 2 [10]
Triciribine prodrug DMBN1XS Solid tumour/cancer 2A00-2F9Z Phase 1/2 [15]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PDK-1 messenger RNA (PDK-1 mRNA) TTYMGWX PDPK1_HUMAN Inhibitor [1]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Inhibitor [2]
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [1]

References

1 Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.
2 Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
3 Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7.
4 US patent application no. 6,124,272, Antisense modulation of PDK-1 expression.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
16 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.